Trial · NCT01357655
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Major Molecular Response | Dasatinib | Baseline | 1 | Participants | |
| Number of Participants With Major Molecular Response | Dasatinib + SMO Antagonist (BMS-833923) | Baseline | 0 | Participants | |
| Number of Participants With Major Molecular Response | Dasatinib | 3 Months | 9 | Participants | |
| Number of Participants With Major Molecular Response | Dasatinib + SMO Antagonist (BMS-833923) | 3 Months | 0 | Participants | |
| Number of Participants With Major Molecular Response | Dasatinib | 6 Months | 30 | Participants | |
| Number of Participants With Major Molecular Response | Dasatinib + SMO Antagonist (BMS-833923) | 6 Months | 0 | Participants | |
| Number of Participants With Major Molecular Response | Dasatinib | 12 Months | 34 | Participants | |
| Number of Participants With Major Molecular Response | Dasatinib + SMO Antagonist (BMS-833923) | 12 Months | 0 | Participants | |
| Number of Participants Experiencing Serious Adverse Events (SAE), Drug-Related Adverse Event (AE), AE Leading to Discontinuation, and Death | Dasatinib | SAE | 18 | participants | |
| Number of Participants Experiencing Serious Adverse Events (SAE), Drug-Related Adverse Event (AE), AE Leading to Discontinuation, and Death | Dasatinib | Drug-Related AE | 56 | participants | |
| Number of Participants Experiencing Serious Adverse Events (SAE), Drug-Related Adverse Event (AE), AE Leading to Discontinuation, and Death | Dasatinib | Death | 2 | participants | |
| Number of Participants Experiencing Serious Adverse Events (SAE), Drug-Related Adverse Event (AE), AE Leading to Discontinuation, and Death | Dasatinib | AE Leading to Discontinuation | 14 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01357655/results